U.S. Department of Health and Human Services: Targeted Capacity Expansion: Medication Assisted Treatment – Prescription Drug and Opioid Addiction
The Targeted Capacity Expansion: Medication Assisted Treatment – Prescription Drug and Opioid Addiction (MAT-PDOA) program aims to expand/enhance access to medication-assisted treatment (MAT) services for persons with an opioid use disorder (OUD) seeking or receiving MAT. The program’s focus is on funding tribes/tribal organizations and organizations and within states identified as having the highest rates of primary treatment admissions for heroin and opioids per capita and includes those states with the most dramatic increases for heroin and opioids. The desired outcomes include: 1) an increase in the number of individuals with OUD receiving MAT; and 2) a decrease in illicit opioid drug use and prescription opioid misuse at six-month follow-up.
MAT using one of the FDA-approved medications for the maintenance treatment of opioid use disorder (methadone, buprenorphine/naloxone products/buprenorphine products including sublingual tablets/film, buccal film, and extended release, long-acting injectable buprenorphine formulations and injectable naltrexone) is a required activity of the program. MAT is to be provided in combination with comprehensive OUD psychosocial services, including, but not limited to: counseling, behavioral therapies, Recovery Support Services (RSS), and other clinically appropriate services required for individuals to achieve and maintain abstinence from opioids.
Amount: A total of $65,583,803 is available to make up to 125 awards that range up to $524,670 per year for up to three years. At least $5,000,000 will be awarded to American Indian/Alaska Native tribes/tribal organizations.
Eligibility: Tribes/tribal organizations across the United States and domestic states, political subdivisions within states, and public and private nonprofit organizations in states with the highest rates of primary treatment admissions for heroin and opioids per capita and includes those with the most dramatic increases for heroin and opioids, as identified by SAMHSA’s 2015 Treatment Episode Data Set (TEDS).
Note: New Mexico is not listed as an eligible state within TEDS (but tribes/tribal organizations in New Mexico are eligible).
This post was filed under: